10-K · March 9, 2026
Vicarious Surgical remains a development-stage robotics company with no product revenue and continuing losses while it advances the single‑port Vicarious Surgical System toward FDA authorization. The filing emphasizes a…
Earnings analysis · 10-Q
RBOT earnings analysis
Filed April 30, 2026 · Our reading of the company's report
The latest report
Vicarious Surgical Inc. reported a net loss of $7,329 for Q1 2026, significantly improved from $15,394 in Q1 2025. However, the company continues to show no revenue generation amidst ongoing operational challenges. The…
Read full summary
Vicarious Surgical Inc. reported a net loss of $7,329 for Q1 2026, significantly improved from $15,394 in Q1 2025. However, the company continues to show no revenue generation amidst ongoing operational challenges. The reduction in net loss highlights cost management, primarily from significant decreases in selling, general, and administrative expenses due to reduced headcount.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Significant Reduction in Net Loss
Net losses decreased from $15,394 in Q1 2025 to $7,329 in Q1 2026.
-
Cost Reductions in Expenses
S&M expenses decreased by 67% to $343, while G&A expenses dropped 60% to $2,120 in Q1 2026.
-
Cash Position Holding Steady
Cash and cash equivalents stood at $1,407, with total short-term investments of $2,275 by March 31, 2026.
-
Operational Cash Flow Improvement
Net cash used in operating activities improved from $11,768 in Q1 2025 to $6,325 in Q1 2026.
What to watch
-
Continued Going Concern Doubts
Management expressed substantial doubt about the company’s ability to continue as a going concern due to insufficient cash to support operations for the next 12 months.
-
NYSE Delisting Risks
The company was delisted from NYSE and is now trading on OTCID, which poses liquidity risks for shareholders.
-
Material Weakness in Internal Controls
The company has identified material weaknesses in its internal controls over financial reporting, which have not been remediated.
Management's outlook
Outlook deferred to earnings press release / call.
Earlier filings 4
10-Q · August 12, 2025
Vicarious Surgical reported no revenue and a Q2 2025 net loss of $13,215 (EPS $(2.23)), an improvement versus Q2 2024 net loss of $15,205 (EPS $(2.59)). Total operating expenses declined to $13,519 in Q2 2025 from…
10-Q · May 12, 2025
Vicarious Surgical reported a Q1 2025 net loss of $15,394 (EPS $(2.60)), an improvement from a $17,001 loss (EPS $(2.90)) in Q1 2024, while still reporting no revenue. Cash and short-term investments totaled $37,362 at…
10-K · March 17, 2025
Vicarious Surgical remains a development-stage medical robotics company: it has not generated any product revenue and continues to incur operating losses while advancing its single‑port Vicarious Surgical System toward…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.